Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00183443 · ClinicalTrials.gov registry record · Phase 3
Treatment of Mania Symptoms With Drug Therapy
A Phase 3 study of Schizophrenia and Bipolar Disorder, sponsored by Palo Alto Veterans Institute for Research.
- Completed
- Registry status
- Phase 3
- Development phase
- 75
- Enrollment target
- 1
- Study location
NCT00183443 is a Phase 3 study of Schizophrenia and Bipolar Disorder that has completed, run by Palo Alto Veterans Institute for Research. The registered enrollment target is 75 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (66% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00183443, a Phase 3 study of Schizophrenia and Bipolar Disorder, has completed, sponsored by Palo Alto Veterans Institute for Research.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 75 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will determine the effectiveness of three different drug therapies in treating the symptoms of mania.
Conditions Studied
Interventions
- DRUG Lithium
- DRUG Quetiapine
- DRUG Divalproex-extended release (DVP-ER)
Study Locations (1)
California
- VA Palo Alto Health Care System - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2005-02 |
| Est. Completion | 2010-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00183443
The ClinicalTrials.gov registry entry for NCT00183443 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (66% lower). The listed sponsor is Palo Alto Veterans Institute for Research, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Schizophrenia appearing as the primary indexed condition, and to 3 interventions - of which Lithium is the first listed.
NCT00183443 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00183443 about?
NCT00183443 is a clinical study titled "Treatment of Mania Symptoms With Drug Therapy". This study will determine the effectiveness of three different drug therapies in treating the symptoms of mania.
What is the current status of trial NCT00183443?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 75 participants. The study started on 2005-02. Estimated completion is 2010-11.
What conditions does trial NCT00183443 study?
This clinical trial studies the following conditions: Schizophrenia, Bipolar Disorder.
What interventions are being tested in trial NCT00183443?
The interventions under investigation include: Lithium (DRUG), Quetiapine (DRUG), Divalproex-extended release (DVP-ER) (DRUG).
Who is sponsoring clinical trial NCT00183443?
This trial is sponsored by Palo Alto Veterans Institute for Research, which has 35 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00183443 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
RECRUITING · Phase 3
-
NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
RECRUITING · Phase 3
-
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
RECRUITING · Phase 3
-
Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
RECRUITING · Phase 3
-
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.